![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Diagnosing sepsis: where we’re at and where we’re going
-
Article
2030: The need for microbiologists and antimicrobial stewardship teams will still remain paramount. Author’s reply
-
Article
2030: will we still need our microbiologist?
-
Article
Trials on oxygen targets in the critically ill patients: do they change our knowledge and practice?
-
Article
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In this context, biomarkers could be considered as indicators of either infection or dysregulated ...
-
Article
Management of diabetic ketoacidosis
-
Article
Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity
-
Article
High oxygen level in traumatic brain injury patients. Never ending story?
-
Article
Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures
Early accurate diagnosis of infection ± organ dysfunction (sepsis) remains a major challenge in clinical practice. Utilizing effective biomarkers to identify infection and impending organ dysfunction before th...
-
Article
The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
-
Article
Challenging management dogma where evidence is non-existent, weak or outdated
Medical practice is dogged by dogma. A conclusive evidence base is lacking for many aspects of patient management. Clinicians, therefore, rely upon engrained treatment strategies as the dogma seems to work, or...
-
Article
“L'histoire se répète”, one size does not fit all. Author’s reply
-
Article
Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions
-
Article
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
Interleukin-6 (IL-6) levels discriminate between patients with mild and severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a systematic review, meta-analysis, trial sequen...
-
Article
Steroids in ARDS: more light is being shed
-
Article
Do critical care patients hibernate? Theoretical support for less is more
-
Article
Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial
Myocardial dysfunction is common in sepsis but optimal treatment strategies are unclear. The inodilator, levosimendan was suggested as a possible therapy; however, the levosimendan to prevent acute organ dysfu...
-
Article
Open AccessCorrection to: Impact on mortality of prompt admission to critical care for deteriorating ward patients: an instrumental variable analysis using critical care bed strain
This article was originally published under a CC BY-NC 4.0 license, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.
-
Article
Open AccessImpact on mortality of prompt admission to critical care for deteriorating ward patients: an instrumental variable analysis using critical care bed strain
To estimate the effect of prompt admission to critical care on mortality for deteriorating ward patients.
-
Article
Open AccessEfficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)
The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for patients with severe community-acq...